Hiltonol + autologous dendritic cells

Hiltonol + autologous dendritic cells is a combination immunotherapy regimen that pairs intratumoral administration of Hiltonol (poly-ICLC), a synthetic double-stranded RNA and potent Toll-like receptor 3 (TLR3) agonist, with vaccination using autologous monocyte-derived dendritic cells loaded ex vivo with tumor lysate. The approach aims to mimic viral infection within the tumor microenvironment to stimulate innate immunity via TLR3 activation and type I interferon induction (by Hiltonol), while simultaneously priming adaptive antitumor immune responses through presentation of patient-specific tumor antigens by the activated dendritic cells. This combination has been investigated in advanced solid tumors and metastatic cancers for its potential to enhance immune-mediated tumor control. Clinical studies have shown it is safe and can induce immunological activity such as increased cytokine production (e.g., IFN-α/β, IL-12) and T-cell reactivity against tumor antigens[1][2][3].

Brand names

Hiltonol

Other names

polyinosinic-polycytidylic acid stabilized with poly-L-lysine and carboxymethylcellulosepoly I:Cautologous dendritic cell vaccineautologous DC vaccine